Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.

This study found that the combination therapy of Flosin and Prostamol Uno over nine years was well tolerated and equally effective in managing benign prostatic hyperplasia symptoms as the combination of doxazosin and finasteride, with fewer adverse events reported.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

This study found that t-flavanone may promote hair growth in people with androgenic alopecia by enhancing hair anchoring strength and upregulating desmoglein expression in hair follicles over 30 weeks.

In this retrospective study, oral minoxidil was found to improve the density of the frontotemporal hairline in 45.1% of patients with frontal fibrosing alopecia, with some also experiencing eyebrow and eyelash growth; however, adverse effects such as hypertrichosis were noted in 33.6% of the participants.

This study reported that combining fexofenadine or ebastine with topical therapy significantly improved hair regrowth and reduced the severity of alopecia areata over 12 weeks compared to topical treatment alone.

In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.

In this clinical experience, treating frontal fibrosing alopecia with oral finasteride, hydroxychloroquine, tacrolimus, and excimer laser was associated with optimal results in patients with active inflammation.

Finasteride 5mg/day improves hair loss in normoandrogenic Asian women.

This systematic review of three randomized controlled trials found that topical eflornithine is an effective adjunctive therapy for reducing unwanted facial hair in women with hirsutism, with benefits lasting at least six months, although efficacy may diminish over time.

This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.

This study found that oral tofacitinib was significantly more effective than oral minoxidil in reducing disease severity and improving treatment response in patients with alopecia areata over a 12-week period.

Taking finasteride daily can effectively and safely increase hair density and thickness for women with hair loss.

In this study, prolonged intravenous Fenoterol infusion was associated with intensive hair growth in most patients, although hormonal changes typically linked to such effects were not observed.

This study found that a topical lotion containing minoxidil, hydrocortisone butyrate, and 17α-estradiol improved or stabilized frontal fibrosing alopecia in 35 out of 40 women over 36 months.

This report describes a case where a woman with frontal fibrosing alopecia initially presented with symptoms resembling rosacea, but further investigation led to a diagnosis of FFA, resulting in a treatment change to oral finasteride and hydroxychloroquine.

The two lotions used day and night may be a good alternative to minoxidil for hair loss treatment with better cosmetic effects and tolerance.

This study found that higher-dose fluconazole (400 mg/d) for two months or longer commonly causes reversible alopecia, which can be resolved by discontinuing or reducing the dosage.

This study found that eflornithine HCl 13.9% cream reduces unwanted facial hair growth in women, with effects seen in up to 60% of participants over 4-8 weeks, with mostly minor skin irritation reported.

This case study reports successful treatment of frontal fibrosing alopecia with daily 2.5mg finasteride in a 77-year-old woman.

This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

This study found that adding topical eflornithine to hair laser treatment significantly reduced hair counts and inflammatory papules more effectively than laser therapy alone in treating pseudofolliculitis barbae.

This abstract explores the roles of dermal fibroblasts and keratinocytes in hair follicle neogenesis and regeneration but does not present new experimental results; it suggests more study is needed on the dermal sheath.